12月16日-12月22日，上交所科创板有3家公司上市；深交所有1家公司上市。 | 数据来源： | | --- | 新 股 上 市 1.元创股份：主要从事橡胶履带类产品的研发、生产和销售。上市首日股价收涨171.64%，截至12月22 日收报54.19元/股，较发行价24.75元/股涨118.95%，总市值约42亿元。 通过上市委员会审议会议 12月16日-12月22日，上交所主板有1家公司过会，科创板有1家公司过会；深交所创业板有2家公司过 会。 | 数据来源： | | --- | 公开信息；图表制作：洞察IPO 公开信息；图表制作：洞察IPO 1.长裕集团：公司主要从事锆类产品、特种尼龙产品、精细化工产品的研发、生产和销售，主要产品包 括氧氯化锆、碳酸锆、氧化锆、纳米复合氧化锆、特种尼龙、长碳链二元酸、长碳链二元醇及长碳链二 甲酯等。 1.昂瑞微：是一家专注于射频、模拟领域的集成电路设计企业。公司主要从事射频前端芯片、射频SoC 芯片及其他模拟芯片的研发、设计与销售。上市首日股价收涨160.11%，截至12月22日收报168.44元/ 股，较发行价83.06元/股涨102.79%，总市值约168亿元。 2 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) announced a significant share transfer agreement that will change its controlling shareholder and actual controller, along with commitments regarding financial performance and asset quality for 2025 [1][2]. Group 1: Share Transfer Agreement - The controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and its action-in-concert party, Shanghai Hangu Investment Management Co., Ltd., signed a share transfer agreement with Zhejiang Xinghao Holding Partnership (Limited Partnership) and its action-in-concert party, Zhejiang Xingchen Equity Investment Partnership (Limited Partnership) [1]. - The transaction involves 14.61% of Asia-Pacific Pharmaceutical's shares, totaling 108,945,566 shares, with a transfer price of 8.26 RMB per share, amounting to approximately 900 million RMB [1]. - Upon completion of the transaction, the controlling shareholder will change from Fubang Group to Xinghao Holding, and the actual controller will shift from the management team to Qiu Zhongxun [1]. Group 2: Financial Commitments - The transferor, Fubang Group and Hangu Investment, committed that the audited main business revenue of Asia-Pacific Pharmaceutical for 2025 will not be less than 360 million RMB [1]. - The lower limit for the net profit, after deducting non-recurring gains and losses, is set at a loss of 70 million RMB for 2025 [1]. - Regarding asset quality, the transferor guarantees that the accounts receivable balance will not exceed 140 million RMB by December 31, 2025, with a recovery rate exceeding 70% by April 25, 2026, and a bad debt rate not exceeding 3% [1]. Group 3: Capital Increase Plan - The company announced a plan to issue no more than 137 million shares, accounting for 18.37% of the pre-issue total share capital, at a price of 5.11 RMB per share [2]. - The total amount of funds raised is expected to be no more than 700 million RMB, which will be used entirely for new drug research and development projects [2]. - The issuance will be subscribed by Zhejiang Xinghao Holding Partnership (Limited Partnership) through cash [2].

Core Viewpoint - The company has approved the use of raised funds to provide loans to its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., for the implementation of a new drug research and development project, amounting to a maximum of RMB 110 million [1][2][10]. Summary of Relevant Sections Fundraising Overview - The company raised a net amount of RMB 590.20 million after deducting issuance costs of RMB 8.37 million, as approved by the China Securities Regulatory Commission [1][2]. - The funds were deposited into a designated account on June 15, 2023, and verified by an accounting firm [1]. Changes in Fund Usage - The company decided to reduce the budget for the "Anti-tumor Drug R&D Project" from RMB 169.20 million to RMB 43.26 million, reallocating the reduced amount of RMB 125.94 million to the "Drug R&D Center and Supporting Facilities Construction Project" [1][2]. - The remaining unused funds from the "Anti-tumor Drug R&D Project" and "Digital Platform Upgrade Project" totaling RMB 103.08 million will now be used for the new drug R&D project at the subsidiary [2][5]. Loan Details - The loan to the subsidiary will be provided in stages based on actual project needs, with a term of 5 years and an interest rate referencing the Loan Prime Rate (LPR) [1][2][10]. - The board of directors has authorized the chairman or designated agents to handle related matters and sign necessary documents [1][10]. Financial Status of the Subsidiary - As of March 31, 2025, the subsidiary had total assets of RMB 670.36 million and total liabilities of RMB 219.90 million, resulting in net assets of RMB 450.46 million [11]. - The subsidiary reported a total revenue of RMB 125.27 million for the first quarter of 2025, with a net loss of RMB 528.35 million for the same period [11]. Related Party Transactions - The loan constitutes a related party transaction, as the subsidiary is controlled by the company, and the terms are deemed fair and reasonable [8][9][10]. - The independent directors and supervisory board have approved the transaction, confirming it aligns with legal regulations and does not harm the interests of shareholders [14][15].

证券代码：002317 公告编号：2025-064 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 备 注 ： 具 体 内 容 详 见 信 息 披 露 媒 体 ：《 证 券 时 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）。 证券代码：002317 公告编号：2025-064 二、《关于开设募集资金专项账户的议案》。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十三次 会议的会议通知于 2025 年 6 月 17 日以专人和电子邮件方式送达全体董事，会议 于 2025 年 6 月 24 日在公司会议室以现场和通讯表决方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、 董事会秘书列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的 有关规定。经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于使用募集资金向控股子公司提供借款实施募投项目暨 关联交易的议案》。 基于部分募投项目变更，为保障项目顺利实施，同意公司使 ...